Publications by authors named "Christine Bus"

There are about 1500 genetic metabolic diseases. A small number of treatable diseases are diagnosed by newborn screening programs, which are continually being developed. However, most diseases can only be diagnosed based on clinical symptoms or metabolic findings.

View Article and Find Full Text PDF

PINK1 loss-of-function mutations cause early onset Parkinson disease. PINK1-Parkin mediated mitophagy has been well studied, but the relevance of the endogenous process in the brain is debated. Here, the absence of PINK1 in human dopaminergic neurons inhibits ionophore-induced mitophagy and reduces mitochondrial membrane potential.

View Article and Find Full Text PDF

Induced pluripotent stem cells (iPSCs) have recapitulated several aspects of Parkinson's disease (PD), but most iPSCs are derived from familial cases, which account for only about 15% of patients. Thus, while the emphasis has justifiably been on using iPSCs to model rare familial cases, models for the most common forms of PD are critically lacking. Here, we report the generation of an iPSC-based model of idiopathic PD (iPD) with or without RS1491923, which is a common risk variant in the LRRK2 locus.

View Article and Find Full Text PDF
Article Synopsis
  • TRAP1 is identified as a key interactor of HTRA2, playing a protective role in mitochondrial dysfunction associated with Parkinson's disease and suggesting it works downstream of both HTRA2 and PINK1.
  • A TRAP1 mutation was discovered in a patient with late-onset Parkinson's, leading to increased oxidative stress and impaired mitochondrial function in their cells.
  • The diabetes drug metformin can reverse some of the negative mitochondrial effects caused by the TRAP1 mutation, highlighting potential new therapeutic approaches for mitochondrial issues in Parkinson's disease.
View Article and Find Full Text PDF

Induced pluripotent stem cells (iPSCs) hold great promise to model diseases, where the disease affected cell type is difficult to access. A major obstacle for the development of disease models is the lack of well characterized control iPSCs from old people not affected by such a disease. Furthermore, gene-editing approaches often require iPSCs from healthy donors, where pathogenic mutations can be inserted if patient material is not available.

View Article and Find Full Text PDF